GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

Paris, France, March 28, 2017, 7.30 CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that three abstracts were accepted for one oral and two poster presentations at the 2017 North American Neuro-Ophthalmology Society (NANOS) 43rd Annual Meeting in Washington, D.C., April 1-6, 2017. Please find the full PDF press release attached. Contacts GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20 NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55 Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017 Source: Gensightgensight_biologics_pr_2017_nanos_20170328